CytomX Launches $250M Public Offering of Stock and Warrants
Summary
CytomX Therapeutics announced the commencement of an underwritten public offering to raise $250.0 million through the sale of common stock and pre-funded warrants, with an option for underwriters to purchase an additional $37.5 million. This substantial capital raise, representing a significant portion of the company's market capitalization, is highly dilutive for existing shareholders. The offering follows the universal shelf registration (S-3ASR) filed just minutes prior, which enabled this capital event. The proceeds are earmarked for the continued development of Varseta-M and other pipeline programs, as well as general corporate purposes. This financing move comes after the company reported a substantial revenue decline and net loss for 2025 earlier today, highlighting the immediate need for capital despite also announcing positive Phase 1 data for Varseta-M.
At the time of this announcement, CTMX was trading at $6.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $0.40 to $8.21. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.